NIOX Group (LON:NIOX) Insider Jonathan Emms Sells 325,273 Shares

Key Points

• Insider sale: Jonathan Emms sold 325,273 NIOX shares on April 16 at an average price of GBX 56, for a total of £182,152.88.
• Market and analyst view: NIOX traded at GBX 57.40 with above-average volume and a market cap of about £240M; Deutsche Bank cut its target from GBX 90 to GBX 86 but the stock still holds a consensus "Buy" with an average target of GBX 86.
• Recent results: The company reported quarterly EPS of GBX 4.03, with a return on equity of 10.14% and a net margin of 14.37%.

NIOX Group Plc (LON:NIOX - Get Free Report) insider Jonathan Emms sold 325,273 shares of the stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of GBX 56, for a total value of £182,152.88.

NIOX Group Price Performance

NIOX traded up GBX 0.80 during trading on Friday, reaching GBX 57.40. 927,740 shares of the company traded hands, compared to its average volume of 816,323. The company has a market cap of £239.97 million, a P/E ratio of 35.00 and a beta of 0.92. The firm has a fifty day simple moving average of GBX 60.84 and a 200 day simple moving average of GBX 66.51. NIOX Group Plc has a 12-month low of GBX 53.84 and a 12-month high of GBX 77.60. The company has a debt-to-equity ratio of 1.36, a quick ratio of 1.94 and a current ratio of 3.81.

NIOX Group (LON:NIOX - Get Free Report) last issued its earnings results on Tuesday, March 24th. The company reported GBX 4.03 earnings per share for the quarter. NIOX Group had a return on equity of 10.14% and a net margin of 14.37%. On average, equities analysts forecast that NIOX Group Plc will post 1.1658256 EPS for the current year.

Analyst Ratings Changes

Separately, Deutsche Bank Aktiengesellschaft lowered their target price on shares of NIOX Group from GBX 90 to GBX 86 and set a "buy" rating on the stock in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of GBX 86.

NIOX Group Company Profile

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings. Headquartered in the UK and listed on the London Stock Exchange ticker: NIOX, the company operates internationally, serving healthcare professionals in over 50 countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.